GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
73.94
+1.16 (+1.59%)
As of 10:25AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close72.78
Open73.30
Bid73.87 x 800
Ask73.88 x 800
Day's Range73.05 - 74.12
52 Week Range64.27 - 89.54
Volume689,211
Avg. Volume6,303,920
Market Cap95.851B
Beta (3Y Monthly)1.40
PE Ratio (TTM)44.17
EPS (TTM)1.67
Earnings DateOct 25, 2018
Forward Dividend & Yield2.28 (3.10%)
Ex-Dividend Date2018-09-13
1y Target Est87.91
Trade prices are not sourced from all markets
  • Trump administration: Drug makers should disclose prices in TV ads
    Yahoo Finance16 hours ago

    Trump administration: Drug makers should disclose prices in TV ads

    just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.

  • Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock
    Motley Fool26 minutes ago

    Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock

    Gilead's high-flying days are seemingly over. Intercept Pharmaceuticals, on the other hand, is only getting started.

  • Gauging Analysts’ Views of Sarepta Stock in October
    Market Realist3 hours ago

    Gauging Analysts’ Views of Sarepta Stock in October

    Of the 23 analysts covering Sarepta Therapeutics (SRPT) in October, eight analysts gave the stock a “strong buy” rating, 14 analysts gave it a “buy” rating, and one analyst gave Sarepta Therapeutics a “hold” rating.

  • A Look at Sarepta Therapeutics’ Stock Performance
    Market Realistyesterday

    A Look at Sarepta Therapeutics’ Stock Performance

    Sarepta Therapeutics (SRPT) has a sponsored research and exclusive license option agreement with Genethon for advancing the latter’s microdystrophin gene therapy program. Sarepta also has a sponsored research and exclusive license option agreement with Duke University for advancing its gene-editing CRISPR/Cas9 technology for muscular dystrophy. Sarepta had submitted a marketing authorization application (or MAA) for eteplirsen to the European Medicines Agency (or EMA) in November 2016.

  • Key Collaborations Bode Well for Sarepta Therapeutics
    Market Realistyesterday

    Key Collaborations Bode Well for Sarepta Therapeutics

    Sarepta Therapeutics (SRPT) is working with several strategic partners for developing multiple treatment approaches to DMD. These partners include Nationwide Children’s Hospital, Myonexus, Genethon, Duke University, and Summit Limited.

  • 2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better
    Motley Foolyesterday

    2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better

    A bad week for the broad market made some generous payouts even more attractive.

  • Analyzing Sarepta’s Product Pipeline
    Market Realistyesterday

    Analyzing Sarepta’s Product Pipeline

    Sarepta Therapeutics’ (SRPT) Exondys 51 uses exon-skipping technology to skip exon 51 of the DMD gene. The drug is designed to bind to exon 51, which leads to an exclusion or skipping of this exon during mRNA processing. Golodirsen uses exon-skipping technology to skip exon 53 of the DMD gene. 

  • Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
    Zacks4 days ago

    Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, Gilead Sciences (GILD) closed at $73.59, marking a +1.5% move from the previous day.

  • Understanding Sarepta Therapeutics’ Operational Performance
    Market Realist4 days ago

    Understanding Sarepta Therapeutics’ Operational Performance

    Sarepta Therapeutics’ (SRPT) cost of sales increased from $506,000 in the second quarter of 2017 to $6.73 million in the second quarter. Sarepta’s cost of sales primarily consists of inventory costs, overhead costs, and royalty payments to BioMarin Pharmaceutical (BMRN). These royalty payments resulted from the settlement and licenses agreements in July 2017. Sarepta Therapeutics’ gross income increased from $34.48 million in the second quarter of 2017 to $66.8 million in the second quarter.

  • Why a Peninsula cancer fighter soared nearly 40% after record-breaking IPO
    American City Business Journals5 days ago

    Why a Peninsula cancer fighter soared nearly 40% after record-breaking IPO

    As the market fell sharply Thursday, this biotech boomed after raising $324 million in an initial public offering.

  • Business Wire5 days ago

    Gilead Sciences to Release Third Quarter 2018 Financial Results on Thursday, October 25, 2018

    Gilead Sciences, Inc. (GILD) announced today that its third quarter 2018 financial results will be released on Thursday, October 25, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the third quarter 2018 and provide a general business update. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 1789278 to access the call.

  • Business Wire5 days ago

    Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting® 2018

    -- More Than 50 Abstracts Across NASH, PSC, HBV and HCV Reflect Ongoing Commitment to Advancing the Care of People with Liver Disease--

  • Healthcare Stocks in the Red amid Broader Market Sell-Off
    Market Realist5 days ago

    Healthcare Stocks in the Red amid Broader Market Sell-Off

    Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.

  • Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates
    Zacks6 days ago

    Arbutus (ABUS) Plunges on Disappointing HBV Pipeline Updates

    Arbutus Biopharma (ABUS) provides updates on its HBV development programs. However, uncertainty and early to mid-stage of development remains a concern.